Multiple Sclerosis | |
|---|---|
| Study Name | Principal Investigator |
| MN43964 – A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab of in Patients with Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| 23-15 HN – Pilot Study to Determine the Effectiveness of the ‘Prescription for Wellness’ for Patients With Multiple Sclerosis. |
Asya Wallach, MD |
| GN41791 – A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult
Patients with Primary Progressive Multiple Sclerosis (FENtrepid). Read more. |
Asya Wallach, MD |
| ICP-CL-00112 – A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity. Read more. |
Mary Ann Picone, MD |
| 257MS201 – A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis (FUSION). Read more. |
Mary Ann Picone, MD |
| EFC17504 – A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis (FREVIVA). Read more. |
Mary Ann Picone, MD |
| BLS-11-404 – A Prospective, Observational Study of BafIertaM Evaluating Persistence on Treatment, Safety, ToLerability, and Effectiveness in Routine Clinical Practice (SIMPLE). Read more. |
Mary Ann Picone, MD |
| ZB012-02-002 – A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab, in Patients with Relapsing Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| MS700568_0186 – Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HAD Switch Study). |
Mary Ann Picone, MD |
